top of page
  • Patient Education

Patient Education: Belantamab Mafodotin-blmf (Blenrep) Antibody Drug Conjugate for Multiple Myeloma

Updated: Mar 27, 2022

Patient Education: Belantamab Mafodotin-blmf

Blenrep - Belantamab Mafodotin-blmf

Belantamab Mafodotin-blmf (Blenrep)

NIH National cancer institute - site info

This page contains brief information and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s): Blenrep

FDA Approved: Yes

Learn more:


MedlinePlus Information

A lay language summary of important information about this drug that may include the following:

warnings about this drug,

what this drug is used for and how it is used,

what you should tell your doctor before using this drug,

what you should know about this drug before using it,

other drugs that may interact with this drug, and

possible side effects.

Learn more:


Information on Blenrep website



Understanding BLENREP (Belantamab Mafodotin-blmf)

Download Booklet here

IMF Understanding Series

IMF Resource Library

Current FDA-Approved Medications for Multiple Myeloma Treatment



All About BLENREP (Belantamab Mafodotin-blmf)

Watch Video on YouTube

HealthTree University for Multiple Myeloma Lectures

Health Tree University Myeloma Videos



Standard Treatments - Blenrep

MMRF Education Programs

MMRF Videos


References BLENREP:

FDA Label Prescribing Information (Revised 02/2022)

Prescribing Information | BLENREP

label (

Medication Guide

Drug Label Information at DAILYMED - NIH-National Library of Medicine

DailyMed - BLENREP- belantamab injection, powder, lyophilized, for solution

Other Resources

Savings & Support


- Multiple Myeloma Patient Education & Information on ongoing Multiple Myeloma Clinical Trials -

Posts Archive
bottom of page